|drug3946||lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Wiki||0.71|
|drug1184||Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet Wiki||0.71|
|D003141||Communicable Diseases NIH||0.05|
There are 2 clinical trials
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.
Description: virus negative conversion rate in second week, overall virus negative conversion rateMeasure: Virus negative conversion rate Time: 14-20 days
Description: defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48hMeasure: Antipyretic rate Time: 14-20 days
Description: time to relieve symptoms of fever, cough, dyspnea, myalgia, etcMeasure: Symptom relief time Time: 14-20 days
Description: no adjuvant oxygen therapy, resting oxygen saturation>95%, oxygenation index>350Measure: Finger oxygen improvement rate Time: 14-20 days
Description: Mild, common type progression to severe or critical illness rateMeasure: Disease progression rate Time: 14-20 days
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global. As the COVID-19 is an emerging infectious disease, it has not scientifically recognized and has no effective drugs for treatment currently. Therefore, we will launch a scientific project "The efficacy and safety of carrimycin treatment in 520 patients with COVID-19 stratificated clinically: A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression. The primary efficiency outcomes were:(1) Fever to normal time (day); (2) Pulmonary inflammation resolution time (HRCT) (day); and (3)Negative conversion (%) of SARS-CoV-2 RNA at the end of treatment. The secondary efficiency outcomes and adverse events were observed.
Description: Fever to normal time (day)Measure: Fever to normal time (day) Time: 30 days
Description: Pulmonary inflammation resolution time (HRCT) (day)Measure: Pulmonary inflammation resolution time (HRCT) (day) Time: 30 days
Description: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatmentMeasure: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment Time: 30 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports